Skip to content
10-Q

Quarterly Report

VitaNova Life Sciences Corporation VNOV

0001683168-24-001418

← back to feed
Filed
Mar 11, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Mar 6, 2024 25.01M sh
Cash And Equivalents Q3 2024 · Jan 31, 2024 $808.36K
Cash And Equivalents Q3 2024 · Apr 30, 2023 $8.73K
Current Liabilities Q3 2024 · Jan 31, 2024 $93.57K
Current Liabilities Q3 2024 · Apr 30, 2023 $67.94K
Total Liabilities Q3 2024 · Jan 31, 2024 $93.57K
Total Liabilities Q3 2024 · Apr 30, 2023 $67.94K
Current Assets Q3 2024 · Jan 31, 2024 $964.36K
Current Assets Q3 2024 · Apr 30, 2023 $8.73K
Total Assets Q3 2024 · Jan 31, 2024 $964.36K
Total Assets Q3 2024 · Apr 30, 2023 $8.73K
Shares Diluted Q3 2024 · Jan 31, 2023 5.87M sh
Shares Diluted Q3 2024 · Jan 31, 2023 5.87M sh
Operating Cash Flow Q3 2024 · Jan 31, 2023 −$16.09K
Stockholders Equity Q3 2024 · Jan 31, 2023 −$54.83K
Stockholders Equity Q3 2024 · Oct 31, 2022 −$30.25K
Stockholders Equity Q3 2024 · Jul 31, 2022 −$32.85K
Stockholders Equity Q3 2024 · Apr 30, 2022 −$34.99K
Eps Diluted Q3 2024 · Jan 31, 2023 $0.00
Eps Diluted Q3 2024 · Jan 31, 2023 $0.00
Eps Basic Q3 2024 · Jan 31, 2023 $0.00
Eps Basic Q3 2024 · Jan 31, 2023 $0.00
Sga Expense Q3 2024 · Jan 31, 2023 $34.58K
Sga Expense Q3 2024 · Jan 31, 2023 $54.84K
Net Income Q3 2024 · Jan 31, 2023 −$24.58K
Net Income Q3 2024 · Jan 31, 2023 −$19.84K
Net Income Q3 2024 · Oct 31, 2022 $2.6K
Net Income Q3 2024 · Jul 31, 2022 $2.13K